Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4947)
All Articles published online
|
Sep 7, 2012 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541 [PMID: 22969226 DOI: 10.3748/wjg.v18.i33.4533] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i33/4533.htm |
| Number | Citing Articles |
| 1 |
Cindy Neuzillet, Annemilaï Tijeras-Raballand, Philippe Bourget, Jérôme Cros, Anne Couvelard, Alain Sauvanet, Marie-Pierre Vullierme, Christophe Tournigand, Pascal Hammel. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacology & Therapeutics 2015; 155: 80 doi: 10.1016/j.pharmthera.2015.08.006
|
| 2 |
Anteneh A. Tesfaye, Hongkun Wang, Marion L. Hartley, Aiwu Ruth He, Louis Weiner, Nina Gabelia, Lana Kapanadze, Muhammad Shezad, Jonathan R. Brody, John L. Marshall, Michael J. Pishvaian. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Pancreatic Cancer 2019; 5(1): 12 doi: 10.1089/pancan.2019.0003
|
| 3 |
Yunpeng Wang, Bofang Wang, Lin Xiang, Junge Deng, Bo Xu, Puyi He, Weigao Pu, Haiyun Wang, Yong Fan, Hao Chen. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1016647
|
| 4 |
Cindy Neuzillet, Sébastien Gaujoux, Nicolas Williet, Jean-Baptiste Bachet, Lucile Bauguion, Laurianne Colson Durand, Thierry Conroy, Laetitia Dahan, Marine Gilabert, Florence Huguet, Lysiane Marthey, Julie Meilleroux, Louis de Mestier, Bertrand Napoléon, Fabienne Portales, Antonio Sa Cunha, Lilian Schwarz, Julien Taieb, Benoist Chibaudel, Olivier Bouché, Pascal Hammel. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Digestive and Liver Disease 2018; 50(12): 1257 doi: 10.1016/j.dld.2018.08.008
|
| 5 |
Fluorouracil/folinic acid/irinotecan. Reactions Weekly 2021; 1851(1): 165 doi: 10.1007/s40278-021-94255-4
|
| 6 |
E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research 2021; 27(23): 6314 doi: 10.1158/1078-0432.CCR-21-1789
|
| 7 |
Anna M. Varghese, Maeve A. Lowery, Kenneth H. Yu, Eileen M. O'Reilly. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016; 122(24): 3765 doi: 10.1002/cncr.30342
|
| 8 |
Anteneh Tesfaye, Philip A. Philip. Textbook of Gastrointestinal Oncology. 2019; : 255 doi: 10.1007/978-3-030-18890-0_15
|
| 9 |
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc, Richard A Hubner, Chang-Fang Chiu, Gilberto Schwartsmann, Jens T Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D Von Hoff, Li-Tzong Chen, Clarence Adoo, Thomas Anderson, Jamil Asselah, Alan Azambuja, Carolyn Bampton, Carlos Henrique Barrios, Tanios Bekaii-Saab, Melichar Bohuslav, David Chang, Jen-Shi Chen, Yeu-Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csoszi, Antonio Cubillo, Linda DeMarco, Maike de Wit, Tomislav Dragovich, William Edenfield, Luis Enrique Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Iaffaioli, Jitka Jakesova, Zsuzsanna Kahan, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, Istvan Lang, Fa-Chyi Lee, Kuan-Der Lee, Lara Lipton, Wen Wee Ma, Laszlo Mangel, Raul Mena, Daniel Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gallego Plazas, Cooray Prasad, Kun-Ming Rau, Jean-Luc Raoul, Donald Richards, Paul Ross, Luis Schlittler, Martin Smakal, Vladimira Stahalova, Cora Sternberg, Thomas Seufferlein, Niall Tebbutt, Jeferson Jose Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet 2016; 387(10018): 545 doi: 10.1016/S0140-6736(15)00986-1
|
| 10 |
M. Bupathi, D. H. Ahn, C. Wu, K. K. Ciombor, J. A. Stephens, J. Reardon, D. A. Goldstein, T. Bekaii-Saab. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology 2016; 33(4) doi: 10.1007/s12032-016-0753-9
|
| 11 |
Rosella Spadi, Federica Brusa, Agostino Ponzetti, Isabella Chiappino, Nadia Birocco, Libero Ciuffreda, Maria Antonietta Satolli. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology 2016; 7(1): 27-43 doi: 10.5306/wjco.v7.i1.27
|
| 12 |
Hangyu Zhang, Zhou Tong, Lulu Liu, Qihan Fu, Xudong Zhu, Xiaomeng Dai, Xuanwen Bao, Weijia Fang, Yi Zheng, Peng Zhao. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study. Gastroenterology Report 2022; 11 doi: 10.1093/gastro/goac088
|
| 13 |
George Kim, Paul Cockrum, Andy Surinach, Shu Wang, Zev Wainberg. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Current Medical Research and Opinion 2022; 38(8): 1295 doi: 10.1080/03007995.2022.2059976
|
| 14 |
Iago Dillion Lima Cavalcanti. Chemotherapy Protocols and Infusion Sequence. 2022; : 125 doi: 10.1007/978-3-031-10839-6_5
|
| 15 |
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology 2020; 12: 175883592094797 doi: 10.1177/1758835920947970
|
| 16 |
Shuyi Li, Mengke Niu, Wenying Deng, Ning Li, Chen Wei, Suxia Luo. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report. Anti-Cancer Drugs 2022; 33(1): e558 doi: 10.1097/CAD.0000000000001173
|
| 17 |
Anant Ramaswamy, Sangeetha Parthiban, Mridul Malhotra, Rushabh Kothari, Alok Goel, Prabhat Bhargava, Sujay Srinivas, Suyash Kulkarni, Vikas Ostwal. Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer 2018; 55(2): 144 doi: 10.4103/ijc.IJC_553_17
|
| 18 |
L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6142-y
|
| 19 |
Medhavi Gupta, Renuka Iyer, Christos Fountzilas. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers 2019; 11(12): 1980 doi: 10.3390/cancers11121980
|
| 20 |
Fausto Petrelli, Alessandro Inno, Antonio Ghidini, Lorenza Rimassa, Gianluca Tomasello, Roberto Labianca, Sandro Barni. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. European Journal of Cancer 2017; 81: 174 doi: 10.1016/j.ejca.2017.05.025
|
| 21 |
Emma Kipps, Kate Young, Naureen Starling. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology 2017; 9(3): 159 doi: 10.1177/1758834016688816
|
| 22 |
GUANG-LIN YANG, HAI-RONG TAO, HAN-WEI WANG, YUN SUN, LI-DI ZHANG, CHAO ZHANG, WEI HE, MANG-HUA XU, JIANG-MIN ZHAO, FENG-HOU GAO. Ara-C increases gastric cancer cell invasion by upregulating CD-147-MMP-2/MMP-9 via the ERK signaling pathway. Oncology Reports 2015; 33(4): 2045 doi: 10.3892/or.2015.3748
|
| 23 |
Aleksandra Adamska, Alice Domenichini, Marco Falasca. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences 2017; 18(7): 1338 doi: 10.3390/ijms18071338
|
| 24 |
Sara Cherri, Silvia Noventa, Alberto Zaniboni. Pancreatic adenocarcinoma: Beyond first line, where are we?. World Journal of Gastroenterology 2021; 27(17): 1847-1863 doi: 10.3748/wjg.v27.i17.1847
|
| 25 |
Lisa Lellouche, Lola-Jade Palmieri, Solène Dermine, Catherine Brezault, Stanislas Chaussade, Romain Coriat. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology 2021; 13: 175883592110185 doi: 10.1177/17588359211018539
|
| 26 |
Ahmad R. Cheema, Eileen M. O’Reilly. Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America 2016; 96(6): 1391 doi: 10.1016/j.suc.2016.07.011
|
| 27 |
Justin C. Tossey, Joshua Reardon, Jeffrey B. VanDeusen, Anne M. Noonan, Kyle Porter, Matthew J. Arango. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Medical Oncology 2019; 36(10) doi: 10.1007/s12032-019-1309-6
|
| 28 |
Concetta Elisa Onesti, Adriana Romiti, Michela Roberto, Rosa Falcone, Paolo Marchetti. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy 2015; 15(10): 1183 doi: 10.1586/14737140.2015.1081816
|
| 29 |
Efrat Dotan, Paul Catalano, Leon Lenchik, Robert Boutin, Xin Yao, Helga S. Marques, Dina Ioffe, David B. Zhen, Daneng Li, Lynne I. Wagner, Melissa A. Simon, Terence Z. Wong, Peter J. O'Dwyer. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. Journal of Geriatric Oncology 2023; 14(3): 101474 doi: 10.1016/j.jgo.2023.101474
|
| 30 |
Brice Leyrat, Maureen Bernadach, Angeline Ginzac, Sejdi Lusho, Xavier Durando. Sister Mary Joseph Nodules: A Case Report about a Rare Location of Skin Metastasis. Case Reports in Oncology 2021; 14(1): 664 doi: 10.1159/000515298
|
| 31 |
Heejung Chae, Hyehyun Jeong, Jaekyung Cheon, Hong Jae Chon, Hyewon Ryu, Il-Hwan Kim, Myoung Joo Kang, Jae Ho Jeong, Baek-Yeol Ryoo, Kyu-pyo Kim, Changhoon Yoo. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Therapeutic Advances in Medical Oncology 2020; 12: 175883592092342 doi: 10.1177/1758835920923424
|